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ABSTRACT
Objectives: The Coronary Revascularisation Outcome
Questionnaire (CROQ) is a patient-reported outcome
measure (PROM) for coronary artery bypass surgery
(CABG) and percutaneous coronary intervention (PCI).
We tested the psychometric properties of a modified
version (CROQv2) when administered in a National
Health Service (NHS)/Department of Health (DH)
funded pilot of PROMs for coronary revascularisation.
Design: Psychometric validation study.
Setting: 11 English hospitals in the UK taking part in
the NHS/DH funded pilot of PROMs for coronary
revascularisation.
Participants: Comprehensive analyses of
acceptability, reliability, validity and responsiveness
were conducted independently for each of the
prerevascularisation (n=2685 and n=3711) and
postrevascularisation (n=869 and n=837) versions of
the CROQ-CABG and CROQ-PCI, respectively.
Results: All versions met prespecified stringent
criteria for (1) acceptability of items (missing data)
and scales (missing data, floor and ceiling effects,
skewness); (2) tests of scaling assumptions; (3)
reliability: internal consistency (Cronbach’s α, item-
total correlations); (4) construct validity based on
within-scale analyses (internal consistency,
intercorrelations between scales, factor analysis and
hypothesis testing); (5) construct validity based on
comparisons with external measures (convergent
and discriminant validity and hypothesis testing) and
(6) responsiveness. Results were also confirmed
when tests were repeated on subsamples of CABG
(n=639) and PCI (n=615) patients who reported
receiving help completing prerevascularisation
questionnaires.
Conclusions: The availability of a psychometrically
robust procedure-specific tool that could be used as
part of a large-scale coronary revascularisation
PROMs programme to capture the patients’
perspective of coronary revascularisation will enable
outcomes important to patients to be routinely
collected alongside clinical outcomes. The CROQ is
suitable for administration by postal survey or the
prerevascularisation versions can be administered in
the clinical setting as in the Coronary
Revascularisation PROMs Pilot.
INTRODUCTION
Patient-reported outcome measures (PROMs)
measure health status and health-related
quality of life (HRQoL) from the patients’
perspective. There is growing interest in cap-
turing PROMs data for patients with coronary
heart disease and other cardiac conditions
and there are numerous disease-speciﬁc tools
available.1 However, most have been devel-
oped to evaluate HRQoL in medically rather
than surgically treated patients, and many
have not been rigorously validated.2
The Coronary Revascularisation Outcome
Strengths and limitations of this study
▪ The Coronary Revascularisation Outcome
Questionnaire includes a much broader range of
outcomes important to patients than other
cardiac-specific questionnaires.
▪ The availability of a tool suitable for use in
large-scale patient-reported outcome measures
(PROMs) programmes, alongside the collection
of clinical data, could enable the routine collec-
tion of outcomes that matter to coronary revas-
cularisation patients, rather than focus on narrow
aspects of disease or functioning.
▪ Psychometric validation is an iterative process; it
is from repeated use in large samples that we
can gain confidence that PROMs are measuring
what they intend to measure in a reliable way
and are able to detect important change.
▪ Large-scale psychometric validation of a
procedure-specific PROM for coronary revascu-
larisation in 11 hospitals in the UK.
▪ Unable to measure test–retest reliability.
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Questionnaire (CROQ)3 4 is a PROM to evaluate health
status and HRQoL in patients undergoing coronary
artery bypass graft surgery (CABG) and percutaneous
coronary intervention (PCI). It was developed and vali-
dated in 2000, as a self-administered survey tool to evalu-
ate outcomes in research and clinical audit, at
prerevascularisation and 3-months postrevascularisation.
It is currently the only disease-speciﬁc tool developed
speciﬁcally to measure health outcomes before and after
coronary revascularisation with some demonstrated evi-
dence of reliability, validity and responsiveness, but has
not been used widely.
PROMs are most commonly used to measure the
impact of healthcare in research and audit but in recent
years have been used to compare the performance of
healthcare providers.5 Since 2009, the National Health
Service (NHS) in England has used PROMs to assess
outcomes in four elective surgical procedures (hip and
knee replacement, varicose vein surgery and groin
hernia surgery) on a routine basis for the purpose of
service evaluation.5–7 NHS England and the Department
of Health (DH) also use the data to monitor progress
towards strategic objectives, such as those speciﬁed in
the NHS Outcomes Framework.8 The NHS Coronary
Revascularisation PROMs Pilot was launched in
November 2011 in order to evaluate the feasibility of
extending the NHS PROMs programme to patients
before and after coronary revascularisation.9 The pilot
was established to examine the feasibility of collecting
PROMs data from patients selected for elective ﬁrst-time
coronary revascularisation across 11 hospitals in England.
Consistent with the PROMs being collected routinely in
other procedures5–7 the DH chose to use the generic
EQ-5D-3L10 alongside a procedure-speciﬁc instrument.
The CROQ3 4 was chosen as the procedure-speciﬁc
instrument by the DH despite it not having been used
widely, as it had demonstrated preliminary evidence of
psychometric robustness, included a broader range of
outcomes than other cardiovascular-speciﬁc measures,
and was speciﬁc to coronary revascularisation.2
It is essential that PROMs satisfy certain development,
psychometric and scaling standards if they are to provide
reliable and valid information for decision making.
Classical Test Theory (CTT),11–15 the traditional psycho-
metric approach, is the most dominant paradigm in the
development of PROMs.16 Within CCT, well-established
methods and criteria are applied to indicate that the
concept, that is, represented by the PROM is clear and well
understood; that the content is relevant to the patient
group concerned; that the psychometric properties
(acceptability, reliability, validity, responsiveness) are
adequate; and that the scaling structure is justiﬁed.17–19
The psychometric properties of a PROM are sample and
context dependent within the CTT paradigm.18 19
Psychometric validation is an iterative process;17 it is from
repeated use in large samples that we can gain conﬁdence
that PROMs are measuring what they intend to measure in
a reliable way and are able to detect important change.18 19
Psychometric properties are inﬂuenced by how people
respond and this can be inﬂuenced by many factors
including use in different patient groups, a change in
the mode of administration or setting, a change in the
assessment point, minor changes to phrasing, question
order or response format.18–23 Completion of PROMs by
persons other than the patient can introduce bias; for
example, family and professionals tend to underestimate
patient’s quality of life status across diverse cultures and
health conditions.24 All changes made to the original
version of an instrument require revalidation of the
instrument, when used in a new context.18 For use in
the NHS Coronary Revascularisation PROMs Pilot,
changes were made to the original version of the CROQ
(necessitating a new version, CROQv2), including some
changes to the text, a change to the postrevascularisa-
tion assessment point (from 3 to 6 months postrevascu-
larisation), method of administration, setting of
administration and sampling frame (see table 1 and
online supplementary appendices 1–4). The NHS
Coronary Revascularisation PROMs Pilot, also included a
much larger, and potentially wider group of patients in
terms of demographic proﬁle and case mix to the
sample used to validate CROQv1. These changes neces-
sitated a re-evaluation of the psychometric properties of
the CROQ in the new context. We describe the psycho-
metric validation of CROQv2 in the context of the NHS
Coronary Revascularisation PROMs Pilot.
METHODS
Samples
The samples described in this paper are those used for
the psychometric validation only and are a subset of all
the patient data gathered in the main NHS Coronary
Revascularisation PROMs Pilot.
Prerevascularisation (Q1) samples
All NHS PROMs Pilot patients waiting for coronary
revascularisation who completed a prerevascularisation
(Q1) questionnaire were included except those cate-
gorised as ineligible (n=63) or duplicates (n=31). A total
of 6396 (2685 CABG and 3711 PCI) patients were
included.
Postrevascularisation (Q2) samples
Patients were only sent a postrevascularisation (Q2)
questionnaire if they had already completed a Q1 ques-
tionnaire. For consistency with the rest of the NHS
PROMs programme,5 6 the DH intended that the postre-
vascularisation Q2 questionnaire would be sent to
patients at 6 months post procedure in the NHS
Coronary Revascularisation PROMs Pilot. However, in
practice the Q2 was not administered at a ﬁxed interval
of 6 months after the revascularisation date, and there
was wide variation in the interval between the revascular-
isation procedure and Q2 completion. For the Q2 psy-
chometric analysis, only patients who completed a Q2
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questionnaire within 5–7 months of a linked Hospital
Episode Statistics (HES) revascularisation episode were
included. The Q2 psychometric samples therefore in-
cluded 869 CABG and 837 PCI patients.
Responsiveness samples
Slightly more stringent inclusion criteria were applied to
the responsiveness psychometric samples to evaluate
whether the CROQ was sensitive to change (between Q1
and Q2) in the context of a speciﬁc single elective pro-
cedure. Patients who had an emergency or a repeat
elective coronary revascularisation procedure were
excluded. The responsiveness samples included 865
CABG and 811 PCI patients.
Psychometric evaluation
There is a prerevascularisation and postrevascularisation
version for CABG and PCI. Each of the four versions are
scored to produce four core scales: symptoms, physical
functioning, psychosocial functioning and cognitive
functioning. In addition, the postrevascularisation ver-
sions include additional items that are scored to
produce the satisfaction and adverse effects scales. All
scales are scored on a 0–100 scale with higher scores
reﬂecting better functioning.3
We evaluated the acceptability, reliability, validity and
responsiveness of CROQv2 prerevascularisation and
postrevascularisation versions independently in CABG
and PCI samples using the same widely adopted criteria,
based on CTT, used to validate CROQv1.3 Table 2 pro-
vides an overview of the tests and criteria applied.
Analyses included an evaluation of (1) the acceptability
of items (missing data) and scales (missing data, ﬂoor
and ceiling effects, skewness); (2) tests of scaling assump-
tions; (3) reliability: internal consistency (Cronbach’sα,
item-total correlations); (4) construct validity based on
within-scale analyses (internal consistency, intercorrela-
tions between scales, factor analysis and hypothesis
testing); (5) construct validity based on comparisons with
external measures (convergent and discriminant validity
and hypothesis testing) and (6) responsiveness.
In addition, the same prerevascularisation psychometric
tests were applied to the subgroups of patients (n=639
CABG and n=615 PCI) who reported they received help
completing the Q1 questionnaire in the clinical setting to
see if the psychometric properties of the CROQ were
compromised. The provision of help with questionnaire
completion to respondents might have enabled a wider
group of patients to have been included in this sample,
than in the self-completed only sample. The type of help
received and from whom was not recorded.
Table 1 Changes made to the CROQ instrument or administration of it
Type of change CROQv13 NHS Coronary Revascularisation PROMs Pilot
Textual changes – Owing to changes in clinical practice over time, PCI
is now often performed via the radial artery rather
than the femoral artery in the groin. Textual
changes were necessary for all items in the
CROQ-PCI adverse effects scale.
Assessment
point
Validated for use with patients at pre-coronary and
3-months post-coronary revascularisation.
The postrevascularisation assessment point (Q2)
was changed to 6 months postrevascularisation.
Method of
administration
Prerevascularisation and postrevascularisation
versions were administered by postal survey.
Prerevascularisation questionnaires were
administered in the clinical setting by staff with
assistance provided as required. The reason for
requiring assistance will have varied, for example,
some patients might not have been able to read
English and others might just have needed help
interpreting a single item.
Setting Prerevascularisation and postrevascularisation
versions administered by postal survey to patients’
home addresses. This enabled patients to complete
the questionnaires at leisure and privately outside of
the clinical setting.
Prerevascularisation questionnaires were
administered in the clinical setting with assistance
provided by staff for those requiring it.
Sampling frame English speaking patients undergoing elective
coronary revascularisation procedures at three
hospitals in the UK.
Patients undergoing elective procedures at 11
hospitals in the UK with a potentially different case
mix severity and demographic profile. Patients
speaking all languages were offered the
prerevascularisation questionnaire by staff in the
clinical setting. Staff offered to assist patients, for
example, by reading the questions to patients and
explaining the meaning and a telephone translation
service was available on request.
CROQ, Coronary Revascularisation Outcome Questionnaire; PCI, percutaneous coronary intervention.
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RESULTS
Table 3 shows the respondent characteristics for the
main psychometric samples. There was a higher pro-
portion of male patients (86.0% vs 83.6%) and white
patients (79.6% vs 59.9%) in the CABG Q2 sample
than in the CABG Q1 sample. There was a higher pro-
portion of male patients (77.9% vs 74.9%) and white
patients (85.9% vs 61.1%) in the PCI Q2 sample than
the PCI Q1 sample. PCI patients completing Q2 were
also older on average than those completing Q1
(mean=66.0 (SD 9.7)) versus 64.7 (SD 10.7) years. A
higher proportion of patients in the CABG (23.8%)
and PCI (16.6%) Q1 samples reported that they had
help completing their questionnaires than patients in
the CABG (11.4%) and PCI (8.6%) Q2 samples. This
probably reﬂects the fact that hospital staff was at hand
to help patients complete questionnaires in the clinical
setting at pre-revascularisation.
Table 2 Psychometric tests and criteria*
Psychometric property Definition/test Criteria
Acceptability Quality of data; assessed by completeness
of data and score distributions.
▸ Proportion of missing data for scales
(<10%)3
▸ Low floor/ceiling effects in the
pre-revascularisation samples
(percentage scoring lowest/highest
possible scale scores)
Reliability: internal consistency Extent to which items in a scale measure
the same construct (such as homogeneity of
the scale); assessed by Cronbach’s α,
item-total correlations, and value of α if an
item is deleted from a scale.
▸ Cronbach’s α for scales >0.7013
▸ Item-total correlations >0.3013
▸ Value of α if an item is deleted from scale
should not ‘substantially increase’25
Tests of scaling assumptions Evidence that an item belongs in its own
scale and not another scale (item
convergent and discriminant validity).
▸ Scaling success/failure (item does/does
not correlate significantly higher with own
scale than other scale) and probable
scaling success/failure (item does/does
not correlate more highly, but not
significantly, with own scale than other
scales)26
Construct validity (within scale
analyses)
Evidence that each scale measures a single
construct and that items can be combined to
form scales; assessed on the basis of
evidence of good internal consistency, factor
analysis and correlations between scale
scores.
▸ Internal consistency (Cronbach’s α >0.70)
▸ Principle axis factor analysis (factor
loadings ≥0.30)3
▸ Moderate intercorrelations between scale
scores and evidence of unique reliable
variance (reliability coefficients with
values greater than the intercorrelations
between scales)26
Construct validity (analyses
against external criteria):
convergent and discriminant
validity
Evidence that scales are correlated with
other measures of the same or similar
construct, and not correlated with other
measures of different constructs; assessed
on the basis of correlations between CROQ,
EQ-5D-3L, and age and sex.
▸ Magnitude and direction of correlations
expected to vary according to the
similarity of constructs being measured in
each instrument
▸ Low to moderate correlations expected
between a disease-specific and generic
tool
▸ Very low correlations (<0.30) expected for
age and sex
Construct validity (analyses
against external criteria):
hypothesis testing
Evidence that scales differentiate known
groups; assessed by comparing CROQ
scores between groups hypothesised to
differ.
▸ CROQ scores should be significantly
(p<0.05) different for groups expected to
differ
Responsiveness Ability of scales to detect clinically important
change over time between Q1 and Q2.
Assessed by effect sizes (mean change
score between prerevascularisation and
postrevascularisation divided by the SD of
scores at pre-revascularisation).
▸ Effect sizes defined as small (0.20),
medium (0.50) and large (≥0.80)27
*Adapted from Schroter and Lamping 2004.3
CROQ, Coronary Revascularisation Outcome Questionnaire.
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Acceptability
There was a low level of missing data across all items in
each version (prerevascularisation and postrevascularisa-
tion); all scales at prerevascularisation and postrevascu-
larisation had <3% missing data (table 4). Analysis of
missing item data in the more elderly subsamples did
not suggest that it was overly burdensome for elderly
patients. Scale scores were calculated with a possible
score range of 0–100, as described for CROQv1.3 There
were no ﬂoor effects (a high proportion scoring at the
bottom of the scales) in the prerevascularisation or post-
revascularisation samples, but there were ceiling effects
(a high proportion scoring at the top of the scales) in
the postrevascularisation samples, as expected following
effective interventions and small ceiling effects for
Cognitive Functioning at prerevascularisation.
Reliability
Cronbach’s α coefﬁcients for all scales at prerevasculari-
sation and postrevascularisation far exceeded the criter-
ion of >0.7013 indicating excellent internal consistency
(table 4). For all scales in all samples, the value of α if
item was deleted did not substantially increase indicating
that all of the items within each scale were contributing
to the underlying constructs.25 Scales in all versions
demonstrated evidence of homogeneity. All item-total
correlations exceeded the criterion of >0.30,13 the range
of item-total correlations was small to moderate, and the
average item-total correlations were moderate to high.
Tests of scaling assumptions
The results of these tests provided strong conﬁrmatory
evidence that the CROQ items are correctly grouped in
scales in the prerevascularisation and postrevascularisa-
tion versions (table 4).26
Construct validity (within scale analyses)
Construct validity was demonstrated by evidence of high
internal consistency (high values of Cronbach’s α and
moderately high item-total correlations, table 4).
Principal axis factor analysis and the pattern of intercor-
relations between the CROQ scales conﬁrmed the
scaling structure of each version (data not presented).
Analyses of CROQ scale scores showed the expected
pattern for groups hypothesised to differ. For example,
CABG and PCI patients who reported overall improve-
ment in their heart condition at Q2 scored signiﬁcantly
higher (p<0.05) on all four CROQ scales than those
who reported their heart condition as being the same or
worse at Q2 (data not presented).
Construct validity (analysis against external criteria)
Convergent and discriminant validity
CROQ scales at prerevascularisation and postrevasculari-
sation were more highly correlated with the EQ-5D-3L10
dimensions measuring conceptually similar constructs
than with those measuring different constructs (table 5).
The correlation coefﬁcients were low to moderate as
Ta
b
le
3
R
es
po
nd
en
t
ch
ar
ac
te
ris
tic
s:
C
A
B
G
an
d
P
C
Is
am
pl
es
C
A
B
G
p
re
re
va
sc
u
la
ri
sa
tio
n
(Q
1)
sa
m
p
le
(N
=2
68
5)
*
C
A
B
G
p
o
st
re
va
sc
u
la
ri
sa
tio
n
(Q
2)
sa
m
p
le
(N
=8
69
)†
P
C
I
p
re
re
va
sc
u
la
ri
sa
tio
n
(Q
1)
sa
m
p
le
(N
=3
71
1)
*
P
C
I
p
o
st
re
va
sc
u
la
ri
sa
tio
n
(Q
2)
sa
m
p
le
(N
=8
37
)†
M
ea
n
(S
D
)
ag
e
in
ye
ar
s
66
.4
(9
.7
)
66
.7
2
(8
.7
)
64
.7
(1
0.
7)
66
.0
(9
.7
)
M
ed
ia
n
(L
Q
,U
Q
)
ag
e
in
ye
ar
s
67
.0
(6
0.
0,
74
.0
)
67
.0
(6
1.
0,
73
.0
)
65
.0
(5
7.
0,
73
.0
)
66
.0
(5
9.
0,
74
.0
)
N
um
be
r
(p
ro
po
rt
io
n)
m
al
es
22
45
(8
3.
6)
74
7
(8
6.
0)
27
78
(7
4.
9)
65
2
(7
7.
9)
N
um
be
r
(p
ro
po
rt
io
n)
liv
in
g
w
ith
pa
rt
ne
r/
sp
ou
se
/fa
m
ily
/fr
ie
nd
s
21
61
(8
0.
5)
70
6
(8
1.
2)
29
70
(8
0.
0)
69
5
(8
3.
0)
N
um
be
r
(p
ro
po
rt
io
n)
liv
in
g
al
on
e
46
8
(1
7.
4)
14
6
(1
6.
8)
64
1
(1
7.
3)
13
0
(1
5.
5)
N
um
be
r
(p
ro
po
rt
io
n)
co
ns
id
er
in
g
th
em
se
lv
es
to
ha
ve
a
di
sa
bi
lit
y
78
5
(2
9.
2)
18
1
(2
0.
8)
13
40
(3
6.
1)
26
1
(3
1.
2)
N
um
be
r
(p
ro
po
rt
io
n)
re
ce
iv
in
g
he
lp
co
m
pl
et
in
g
qu
es
tio
nn
ai
re
63
9
(2
3.
8)
99
(1
1.
4)
61
5
(1
6.
6)
72
(8
.6
)
N
um
be
r
(p
ro
po
rt
io
n)
of
ea
ch
et
hn
ic
gr
ou
p‡
W
hi
te
16
08
(5
9.
9)
69
2
(7
9.
6)
22
68
(6
1.
1)
71
9
(8
5.
9)
M
ix
ed
9
(0
.3
)
4
(0
.5
)
12
(0
.3
)
6
(0
.7
)
A
si
an
17
8
(6
.6
)
64
(7
.4
)
15
6
(4
.2
)
24
(2
.9
)
B
la
ck
9
(0
.3
)
0
(0
)
15
(0
.4
)
2
(0
.2
)
O
th
er
et
hn
ic
gr
ou
ps
34
(1
.3
)
13
(1
.5
)
33
(0
.9
)
12
(1
.4
)
M
is
si
ng
84
7
(3
1.
5)
96
(1
1.
0)
12
27
(3
3.
1)
74
(8
.8
)
N
um
be
rs
in
br
ac
ke
ts
ar
e
pe
r
ce
nt
s,
un
le
ss
sp
ec
ifi
ed
ot
he
rw
is
e.
N
um
be
rs
do
no
t
su
m
to
10
0%
du
e
to
ro
un
di
ng
or
m
is
si
ng
da
ta
.
*A
ll
pa
tie
nt
s
w
ho
co
m
pl
et
ed
Q
1
re
ga
rd
le
ss
of
w
he
th
er
th
ey
ha
d
a
H
E
S
lin
ke
d
ep
is
od
e
or
w
he
th
er
th
ey
co
m
pl
et
ed
Q
2.
†
P
at
ie
nt
s
w
ho
co
m
pl
et
ed
on
ly
on
e
Q
1
qu
es
tio
nn
ai
re
,
ha
d
a
m
at
ch
ed
H
E
S
lin
ke
d
ep
is
od
e
ba
se
d
on
or
ig
in
al
P
R
O
M
S
pr
og
ra
m
m
e
cr
ite
ria
,w
er
e
se
nt
a
Q
2
at
a
tim
e
ba
se
d
on
th
e
H
E
S
lin
ke
d
ep
is
od
e,
an
d
co
m
pl
et
ed
Q
2
w
ith
in
5–
7
m
on
th
s
of
th
e
H
E
S
lin
ke
d
ep
is
od
e.
‡
ht
tp
://
w
w
w
.d
at
ad
ic
tio
na
ry
.n
hs
.u
k/
da
ta
_d
ic
tio
na
ry
/a
ttr
ib
ut
es
/e
/e
nd
/e
th
ni
c_
ca
te
go
ry
_c
od
e_
de
.a
sp
?s
ho
w
na
v=
1
C
A
B
G
,
co
ro
na
ry
ar
te
ry
by
pa
ss
su
rg
er
y;
LQ
,
lo
w
er
qu
ar
til
e;
P
C
I,
pe
rc
ut
an
eo
us
co
ro
na
ry
in
te
rv
en
tio
n;
U
Q
,
up
pe
r
qu
ar
til
e.
Schroter S, et al. BMJ Open 2017;7:e015915. doi:10.1136/bmjopen-2017-015915 5
Open Access
Table 4 Acceptability, reliability and tests of scaling assumptions for CROQ-CABG and CROQ-PCI
Range of
scores Acceptability Internal consistency Tests of scaling assumptions
CROQ scale Scale Sample % missing
% floor/%
ceiling n
Cronbach’s
α
Mean item-total
correlation
% definite scaling success
(% probable scaling success)
CABG prerevascularisation (N=2685)
Symptoms 0–100 0–100 2.3 0.3/5.5 2622 0.87 0.65 100 (0)
Physical functioning 0–100 0–100 2.1 2.0/10.9 2628 0.91 0.71 100 (0)
Psychosocial functioning 0–100 0–100 1.2 0.1/1.5 2653 0.94 0.72 100 (0)
Cognitive functioning 0–100 0–100 1.2 1.5/30.0 2654 0.90 0.79 100 (0)
PCI prerevascularisation (N=3711)
Symptoms 0–100 0–100 2.6 0.3/4.2 3616 0.89 0.69 100 (0)
Physical functioning 0–100 0–100 2.1 3.7/10.0 3632 0.92 0.74 100 (0)
Psychosocial functioning 0–100 0–100 1.2 0.5/1.7 3665 0.95 0.74 100 (0)
Cognitive functioning 0–100 0–100 1.2 1.8/28.4 3667 0.91 0.81 100 (0)
CABG postrevascularisation (N=869)
Symptoms 0–100 6–100 2.2 0.0/33.1 850 0.88 0.67 100 (0)
Physical functioning 0–100 0–100 2.0 0.7/39.8 852 0.93 0.76 100 (0)
Psychosocial functioning 0–100 0–100 0.5 0.1/13.2 865 0.96 0.77 100 (0)
Cognitive functioning 0–100 0–100 0.6 0.3/41.4 864 0.91 0.82 100 (0)
Adverse effects 0–100 0–100 0.6 0.1/13.1 864 0.86 0.56 100 (0)
Satisfaction 0–100 0–100 0.1 0.1/33.3 868 0.79 0.57 100 (0)
PCI postrevascularisation (N=837)
Symptoms 0–100 0–100 2.6 0.1/23.4 815 0.91 0.73 100 (0)
Physical functioning 0–100 0–100 2.4 1.4/35.5 817 0.94 0.80 100 (0)
Psychosocial functioning 0–100 5–100 0.5 0.0/11.0 833 0.96 0.78 93 (7)
Cognitive functioning 0–100 0–100 0.8 0.6/36.9 830 0.90 0.80 100 (0)
Adverse effects 0–100 0–100 1.3 0.1/70.3 826 0.84 0.62 100 (0)
Satisfaction 0–100 0–100 0.2 0.5/26.9 835 0.83 0.61 100 (0)
CABG, coronary artery bypass surgery; CROQ, Coronary Revascularisation Outcome Questionnaire; PCI, percutaneous coronary intervention.
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expected between a disease-speciﬁc and generic tool,
and slightly higher at postrevascularisation. As hypothe-
sised there were very low correlations (all <0.30)
between each version of the CROQ and age and sex,
demonstrating that scores are not biased by these demo-
graphic factors.
Hypothesis testing/known groups (analyses against external
criteria)
The EQ-5D-3L User Guide advises that levels 2 (some
problems) and 3 (extreme problems) are combined into
a single category (problems) as extreme problems are
often low in frequency. While extreme problems were
reported by some patients for some EQ-5D dimensions,
the numbers were small for this level for other dimen-
sions so the levels were collapsed for all dimensions. As
hypothesised, mean CROQ scale scores were signiﬁ-
cantly higher (p<0.001) for those reporting ‘no pro-
blems’ than ‘problems’ on the ﬁve EQ-5D-3L
dimensions, at prerevascularisation and postrevasculari-
sation in the CABG and PCI samples (web tables S1 and
S2). In addition, on average, CABG and PCI patients
reporting a comorbidity of depression scored signiﬁ-
cantly lower (p<0.05) on all CROQ scales, at prerevascu-
larisation and postrevascularisation.
Responsiveness
Table 6 shows the effect sizes for change between prere-
vascularisation and postrevascularisation for the four
core scales in the CABG and PCI responsiveness
samples. All scales demonstrated signiﬁcant change
between prerevascularisation and postrevascularisation
(p<0.001). For the CROQ-CABG, there was a large27
effect size for symptoms and psychosocial functioning, a
moderate effect size for physical functioning, and a
small effect size for cognitive functioning. For the
CROQ-PCI, there was a large effect size for symptoms,
moderate effect sizes for physical functioning and psy-
chosocial functioning and a very small effect size for cog-
nitive functioning. In the CABG and PCI samples, the
generic EQ-5D-3L visual analogue scale (VAS) score had
a smaller effect size (was less responsive) than three of
the four disease-speciﬁc CROQ scales.
Subsamples of patients reporting having received help
with the Q1 questionnaire
A signiﬁcantly higher proportion of patients receiving
help completing the Q1 questionnaire compared with
those who did not receive help were female (CABG:
21.3% vs 14.5%; PCI: 30.4% vs 23.9%, p=.001) and
Table 5 Construct validity (convergent and discriminant validity): CROQ-CABG and CROQ-PCI correlations with EQ-5D-3L
EQ-5D-3L dimensions
EQ-5D-3L
VAS score
CROQ scale Mobility Self-care
Usual
activities
Pain and
discomfort
Anxiety and
depression
CABG prerevascularisation (n=2685)
Symptoms −0.41 −0.26 −0.42 −0.59 −0.27 0.47
Physical functioning −0.58 −0.40 −0.55 −0.49 −0.27 0.52
Psychosocial functioning −0.40 −0.29 −0.52 −0.46 −0.57 0.55
Cognitive functioning −0.32 −0.29 −0.38 −0.35 −0.44 0.41
PCI prerevascularisation (n=3711)
Symptoms −0.46 −0.30 −0.46 −0.59 −0.32 0.50
Physical functioning −0.62 −0.47 −0.57 −0.50 −0.31 0.56
Psychosocial functioning −0.48 −0.42 −0.57 −0.48 −0.57 0.59
Cognitive functioning −0.36 −0.40 −0.41 −0.38 −0.49 0.45
CABG postrevascularisation (N=869)
Symptoms −0.43 −0.37 −0.52 −0.50 −0.47 0.54
Physical functioning −0.63 −0.55 −0.68 −0.52 −0.45 0.60
Psychosocial functioning −0.50 −0.51 −0.64 −0.56 −0.68 0.65
Cognitive functioning −0.41 −0.47 −0.53 −0.46 −0.54 0.50
Adverse effects −0.35 −0.40 −0.45 −0.55 −0.44 0.45
Satisfaction −0.34 −0.26 −0.48 −0.44 −0.44 0.52
PCI postrevascularisation (N=837)
Symptoms −0.53 −0.38 −0.56 −0.61 −0.44 0.60
Physical functioning −0.71 −0.57 −0.71 −0.50 −0.41 0.68
Psychosocial functioning −0.60 −0.51 −0.66 −0.56 −0.65 0.67
Cognitive functioning −0.49 −0.41 −0.52 −0.40 −0.56 0.53
Adverse effects −0.25 −0.25 −0.23 −0.26 −0.18 0.21
Satisfaction −0.35 −0.27 −0.42 −0.41 −0.34 0.47
Values in bold indicate correlations between scores that purport to measure similar aspects of HRQoL.
The correlations with the EQ-5D-3L dimension scores are negative as higher scores on these indicate poor functioning whereas higher scores
on the CROQ and EQ-5D-3L VAS score indicate better functioning.
CABG, coronary artery bypass surgery; CROQ, Coronary Revascularisation Outcome Questionnaire; HRQoL, health-related quality of life;
PCI, percutaneous coronary intervention.
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considered themselves to have a disability (CABG 41.8%
vs 26.4%; PCI: 58.4% vs 33.3%, p<0.001). A signiﬁcantly
lower proportion of CABG patients receiving help were
white (49.8% vs 63.1%, p<0.001). CABG patients (68.6
(SD 9.9) years vs 65.6 (SD 9.5) years) and PCI patients
(68.4 (SD 10.9) years vs 63.85 (SD 10.5) years) who
received help were also signiﬁcantly older (p<0.001) and
scored signiﬁcantly lower on all four core scales of the
CROQ and the EQ-5D-3L VAS Score (p<0.001), than
those who did not receive help. All tests of acceptability,
scaling assumptions, reliability and validity met the same
psychometric criteria when they were repeated for just the
subsamples of patients who reported that they received
help completing the prerevascularisation versions in the
clinical setting (n=639 CABG and n=615 PCI).
DISCUSSION
Traditional psychometric properties of PROMs are
context and sample dependent.18 19 Traditional psycho-
metric analyses showed that the prerevascularisation and
postrevascularisation versions of the CROQ-CABG and
CROQ-PCI demonstrated sufﬁcient evidence of accept-
ability, reliability (internal consistency), validity and
responsiveness when used in the context of the NHS
Coronary Revascularisation PROMs Pilot, for the sample
of patients whose postprocedure assessment point was
ﬁxed to between 5 and 7 months of a HES conﬁrmed
revascularisation procedure. Analyses also conﬁrmed
that the prerevascularisation versions of CROQv2 are
robust for self-completion and for completion with
patient-reported help when administered in a clinical
setting.
The initial psychometric validation of CROQv1
showed it to be acceptable, reliable, valid and responsive
when administered via postal survey, in the context of a
research project, in selected samples of patients at
prerevascularisation and 3 months postrevascularisa-
tion.3 4 The analysis described in this paper conﬁrms
that the psychometric properties for CROQv2 are also
robust when it is administered to a more diverse and
larger number of patients undergoing elective coronary
revascularisation procedures, outside of the context of a
research project. The CROQ was developed as a self-
administered postal survey, but our subgroup analysis
demonstrated that the psychometric properties were not
compromised when patients received help in the clinical
setting, despite the fact that research has shown that
family and professionals tend to underestimate patients
quality of life status across diverse cultured and health
conditions.24 Our analysis also conﬁrmed that the psy-
chometric properties are withheld when the postrevascu-
larisation version is administered at 5–7 months (rather
than 3 months) postrevascularisation by postal survey. As
such it is appropriate to administer the CROQ at prere-
vascularisation (by survey or in the clinical setting) and
at 3 or 6 months postrevascularisation by postal survey.
This will allow for a greater degree of ﬂexibility in future
study designs and may reduce administration costs.
The CROQ is the only validated disease-speciﬁc PROM
developed speciﬁcally to measure outcomes before and
after coronary revascularisation (CABG and PCI). While
other cardiac-speciﬁc PROMs have been developed
and are relevant for use with coronary heart disease
patients, such as the Seattle Angina Questionnaire,28 the
MacNew Heart Disease Health-Related Quality of Life
Questionnaire,29 and the Quality of Life Index-Cardiac
Version, QLI-CV,30 these questionnaires do not capture
all outcomes of importance to patients before and after
coronary revascularisation.2 While some of these ques-
tionnaires have been widely used with coronary heart
disease patients, including those undergoing CABG and
PCI, for example, the Seattle Angina Questionnaire,
when selecting an instrument it is important to ensure
that the most relevant and applicable PROM is used for
the research question under study, that all the questions
are applicable to the speciﬁc patient group and that
items of importance to patients are included.
Study limitations
This study has some important limitations. First, a large
number of patients had to be excluded from the main
NHS PROMs Pilot postrevascularisation samples, as the
interval when patients were sent their postoperative
questionnaires (Q2) for completion at home, was very
varied. As PROMs are sample and context dependent, to
perform meaningful psychometric analysis, it was essen-
tial to compare patients at a similar point in time after
revascularisation. The possibly slightly lenient criterion
of including patients who completed their postoperative
Q2 questionnaire between 5 and 7 months of a HES
conﬁrmed coronary revascularisation date was applied
to all the postrevascularisation psychometric analysis. In
future applications, if these essential exclusion criteria
are not applied then the psychometric properties of the
Table 6 Responsiveness of CROQv2 from
prerevascularisation to postrevascularisation
CROQ scale
Responsiveness
effect size
CABG responsiveness sample (n=865)
CROQ symptoms 1.06
CROQ physical functioning 0.72
CROQ psychosocial functioning 0.91
CROQ cognitive functioning 0.28
EQ-5D-3L VAS score 0.71
PCI responsiveness sample (n=811)
CROQ symptoms 0.82
CROQ physical functioning 0.52
CROQ psychosocial functioning 0.59
CROQ cognitive functioning 0.19
EQ-5D-3L VAS score 0.42
CABG, coronary artery bypass surgery; CROQ, Coronary
Revascularisation Outcome Questionnaire; PCI, percutaneous
coronary intervention.
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CROQ may be compromised and the data may be
invalid.
Second, it was not possible to evaluate the stability of
the CROQv2 through test–retest reliability17 as the
appropriate data was not collected during the NHS
PROMs Revascularisation Pilot. This should be assessed
in a small random sample of CABG and PCI patients, if
the decision to use CROQv2 more widely in this context
is made.
Third, at the time the CROQv1 was originally devel-
oped, the dominant psychometric paradigm was CTT
and the CROQv1 was developed using these traditional
methods (as described here). It was therefore important
to assess the psychometric properties of CROQv2 using
the same methods as the original validation. However,
future work could evaluate the CROQv2 using so called
modern psychometric methods such as Item Response
Theory31 or Rasch Measurement Theory.32 This would
enable CROQv2 scores to be placed on a truly interval
scale, to be invariant (ie, independent of sample and
context) and potentially to be applicable in clinical prac-
tice at the individual patient level.33 Currently, CROQv2
should not be used as a tool to assess a patient’s need
for surgery as, like other PROMs, it has not been vali-
dated for this purpose and it is possible that its predict-
ive validity is not strong enough.
Conclusion
The CROQ is reliable, valid and responsive when used
in the context of a large-scale PROMs programme.
While there are several validated cardiac speciﬁc
PROMs, the CROQ remains the only validated
procedure-speciﬁc questionnaire for coronary revascular-
isation. It was developed with patients and includes a
much broader range of outcomes important to patients
than other cardiac-speciﬁc questionnaires. The availabil-
ity of a tool suitable for use in large-scale PROMs pro-
grammes, alongside the collection of clinical data, could
enable the routine collection of outcomes that matter to
coronary revascularisation patients, rather than focus on
narrow aspects of disease or functioning. The CROQ is
not yet appropriate for use in clinical practice at the
individual patient level as it was developed using psycho-
metric tests for group level measurement and more
rigorous measurement standards need to be met for this
application.33
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